Recommendations Antiepileptic drugs to treat pain in rheumatic conditions. Recommendations based on evidence-based review of the literature and expert opinion *

Objectives: Neuropathic pain is commonly encountered in rheumatology practice, often associated with nociceptive mechanisms. It is caused by nervous system lesions, and the usual treatments with analgesics and anti-inflammatory drugs are mostly ineffective. Antiepileptic drugs (AED) have proved effective in relieving neuropathic pain. AED are recently used by rheumatologists since the role of neuropathic pain in rheumatological conditions has only recently been documented. Nevertheless, the tendency seems to be reversed when these drugs are used inappropriately. The CEDR (Cercle d’Etude de la Douleur en Rhumatologie), a specific interest group of the French Society of Rheumatology that focuses on pain in rheumatology, undertook to develop recommendations for the use of AED in Rheumatology. Methods: A list of questions concerning the prescription of AED in painful rheumatic conditions was validated by a working group of 7 experts from the CEDR. The list of questions was used to draw up the recommendations. A literature review was performed using electronic databases (Medline, Embase and Cochrane library between 1980 and 2007) without limitations on the type of publication: case reports, clinical trials, literature review and guidelines about therapeutic management of neuropathic pain. Selected studies were scored for quality. Based on the literature and clinical experience, recommendations were developed using the Delphi method. Results: We identified 29 studies concerning the use of AED in painful rheumatic conditions and 16 studies were considered valid and scored for quality. These few studies, the guidelines published for neuropathic pain treatment and the clinical experience of each expert, were used to develop 11 recommendations for the use of AED in painful rheumatic conditions. Conclusion: These recommendations can be used as guidelines to help prescribers to use AED for the management of pain in rheumatic conditions until further scientific evidence becomes available. 2008 Elsevier Masson SAS. All rights reserved.

[1]  J. Farrar,et al.  Pharmacologic management of neuropathic pain: Evidence-based recommendations , 2007, PAIN.

[2]  P. Keck,et al.  Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. , 2007, Arthritis and rheumatism.

[3]  T. Nurmikko,et al.  EFNS guidelines on pharmacological treatment of neuropathic pain , 2006, European journal of neurology.

[4]  M. Doherty,et al.  EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology , 2006, British Journal of Sports Medicine.

[5]  Peter K. Leiberich,et al.  Topiramate in Treatment of Patients With Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled Study , 2006, The Clinical journal of pain.

[6]  A. Eschalier,et al.  Guidelines for the use of antidepressants in painful rheumatic conditions , 2006, European journal of pain.

[7]  H. J. McQuay,et al.  Algorithm for neuropathic pain treatment: An evidence based proposal , 2005, Pain.

[8]  M. Max,et al.  Topiramate in chronic lumbar radicular pain. , 2005, The journal of pain : official journal of the American Pain Society.

[9]  R. Freeman.  The Treatment of Neuropathic Pain , 2005, CNS Spectrums.

[10]  A. Chaturvedi,et al.  Effect of Preemptive Gabapentin on Postoperative Pain Relief and Morphine Consumption Following Lumbar Laminectomy and Discectomy: A Randomized, Double-Blinded, Placebo-Controlled Study , 2005, Journal of neurosurgical anesthesiology.

[11]  A. Todorov,et al.  Tiagabine and Gabapentin for the Management of Chronic Pain , 2005, The Clinical journal of pain.

[12]  E. Perucca,et al.  An Introduction to Antiepileptic Drugs , 2005, Epilepsia.

[13]  J. Audette,et al.  Neuropathic low back pain , 2005, Current pain and headache reports.

[14]  G. Herrero-Beaumont,et al.  EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2005, Annals of the rheumatic diseases.

[15]  M. Rowbotham,et al.  Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[16]  D. Tu,et al.  Morphine, gabapentin, or their combination for neuropathic pain. , 2005, The New England journal of medicine.

[17]  Bernard Laurent,et al.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) , 2005, Pain.

[18]  A. Douglass,et al.  Evaluation and treatment of low back pain in family practice. , 2004, The Journal of the American Board of Family Practice.

[19]  E. Eisenberg,et al.  Lamotrigine for intractable sciatica: correlation between dose, plasma concentration and analgesia , 2003, European journal of pain.

[20]  Mario Saltarelli,et al.  Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. , 2003, Archives of neurology.

[21]  M. Moskowitz.  Pharmacotherapy of neuropathic low back pain , 2003, Current pain and headache reports.

[22]  S. Perrot,et al.  Les douleurs neuropathiques en rhumatologie , 2002 .

[23]  M. Serpell.  Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial , 2002, Pain.

[24]  D. A. Simpson.  Gabapentin and Venlafaxine for the Treatment of Painful Diabetic Neuropathy , 2001, Journal of clinical neuromuscular disease.

[25]  C. Cooper,et al.  EULAR recommendations for the management of knee osteoarthritis , 2001 .

[26]  J. Devulder,et al.  Lamotrigine in the treatment of chronic refractory neuropathic pain. , 2000, Journal of pain and symptom management.

[27]  P. Shekelle,et al.  Clinical guidelines: developing guidelines. , 1999, BMJ.

[28]  N. Black,et al.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.

[29]  M. Naidu,et al.  Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study. , 1995, The Journal of rheumatology.

[30]  J. Hunter,et al.  Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis. , 1987, Annals of the rheumatic diseases.

[31]  R. Dworkin,et al.  Ion channel targets and treatment efficacy in neuropathic pain. , 2006, The journal of pain : official journal of the American Pain Society.

[32]  L. Baratto,et al.  Low dose gabapentin for shoulder-hand syndrome induced by phenobarbital: a three-month study. , 1999, Drugs under experimental and clinical research.

[33]  M. Naidu,et al.  Evaluation of phenytoin in rheumatoid arthritis--an open study. , 1991, Drugs under experimental and clinical research.